Condition: Hepatocellular Carcinoma (HCC) · Sponsor: Palo Alto Veterans Institute for Research
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
This description comes directly from the study's public registry record.
Sirish Kishore, MD · 650-493-5000 · sirish.kishore@va.gov
Luisa Manfredi, MPH · 650-493-5000 · luisa.manfredi1@va.gov
Always discuss trial participation with your own doctor first.
| VA Palo Alto Health Care System | Palo Alto, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07303712